Get the Stockscreener App
160.10
2.96%
4.60
After Hours:
160.00
-0.10
-0.06%
Natera Inc stock is traded at $160.10, with a volume of 1.25M.
It is up +2.96% in the last 24 hours and up +15.80% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$155.50
Open:
$154.5
24h Volume:
1.25M
Relative Volume:
0.80
Market Cap:
$20.52B
Revenue:
$1.53B
Net Income/Loss:
$-214.69M
P/E Ratio:
-90.97
EPS:
-1.76
Net Cash Flow:
$-43.68M
1W Performance:
+6.08%
1M Performance:
+15.80%
6M Performance:
+22.79%
1Y Performance:
+64.80%
1-Day Range:
$153.63
$160.21
1-Week Range:
$146.34
$160.21
52-Week Range:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
160.10 | 20.52B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
407.85 | 161.94B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.09 | 142.65B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
486.61 | 34.79B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
107.52 | 30.67B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.30 | 27.00B | 15.41B | 1.37B | 2.11B | 7.50 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Cathie Wood’s ARK Makes Bold Tuesday Moves with Key Stock Swaps - Wall Street Pit
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - Stock Titan
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas - Medical Device Network
Natera (NTRA) Highlights Promising Study Results for Sarcoma Det - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Breakthrough: Largest-Ever Sarcoma Study Validates Natera's Cancer Detection Test with 93% Accuracy - Stock Titan
Learn to Evaluate (NTRA) using the Charts - news.stocktradersdaily.com
CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the Firm - Newsfile
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action - TradingView
Natera to Report its First Quarter Results on May 8, 2025 - BioSpace
Natera’s chief legal officer sells $303,299 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 By Investing.com - Investing.com Canada
Natera president Solomon Moshkevich sells $335,714 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 - Investing.com Australia
Natera co-founder Sheena Jonathan sells $66,808 in stock By Investing.com - Investing.com Canada
Natera co-founder Sheena Jonathan sells $66,808 in stock - Investing.com Australia
Natera’s chief legal officer sells $303,299 in stock - Investing.com
Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study - Yahoo Finance
Minimal Residual Disease Testing Market Outlook 2024-2031 | Growth Led by Myriad, Natera & Guardant - openPR.com
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now - Insider Monkey
Natera launches Signatera Genome assay nationwide By Investing.com - Investing.com India
Natera Inc (NTRA) Shares Up 3.01% on Apr 24 - GuruFocus
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test - BioSpace
Natera launches Signatera Genome assay nationwide - Investing.com Australia
Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting - marketscreener.com
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting - BioSpace
Natera CFO Michael Burkes Brophy sells $88,784 in stock By Investing.com - Investing.com Nigeria
Natera CFO Michael Burkes Brophy sells $88,784 in stock - Investing.com
Natera Executives and Directors Conduct Share Transactions - TradingView
Natera To Present Data from 8 Studies at 2025 AACR Annual Meetin - GuruFocus
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting | NTRA Stock News - GuruFocus
Long Term Trading Analysis for (NTRA) - news.stocktradersdaily.com
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Benzinga
The Blood Test Revolution Driving These Three Stocks - Investor's Business Daily
Lobbying Update: $140,000 of NATERA INC lobbying was just disclosed - Nasdaq
When will cancer return? Personalized Signatera blood test can find early signs of disease - Austin American-Statesman
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):